A Novel Signature of Lipid Metabolism-Related Gene Predicts Prognosis and Response to Immunotherapy in Lung Adenocarcinoma

Lipid metabolism disorder, a new hallmark of cancer initiation, has been involved in lung adenocarcinoma (LUAD). However, few biomarkers about lipid metabolism-related genes (LMRGs) have been developed for prognosis prediction and clinical treatment of LUAD patients. In this study, we constructed an...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in cell and developmental biology Vol. 10; p. 730132
Main Authors Zhang, Kai, Qian, Ying, Quan, Xiaowei, Zhu, Tengteng, Qian, Biyun
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 28.02.2022
Subjects
Cell and Developmental Biology
immune checkpoint
immunotherapy
lipid metabolism
lung adenocarcinoma
prognosis model
tumor microenvironment
tumor microenvironment
prognosis model
immune checkpoint
immunotherapy
lipid metabolism
lung adenocarcinoma
Online AccessGet full text

Cover

More Information
Summary:Lipid metabolism disorder, a new hallmark of cancer initiation, has been involved in lung adenocarcinoma (LUAD). However, few biomarkers about lipid metabolism-related genes (LMRGs) have been developed for prognosis prediction and clinical treatment of LUAD patients. In this study, we constructed and validated an effective prognostic prediction model for LUAD patients depending on LMRGs. Subsequently, we investigated the prediction model from immune microenvironment, genomic changes, and immunotherapy. Then, eleven LMRGs were identified and applied to LUAD subtyping. In comparison with the high-risk group, the low-risk group exhibited a remarkably favorable prognosis, along with a higher immune score and lower tumor purity. Moreover, the low-risk group presented higher levels of immune checkpoint molecules, lower tumor immune dysfunction and exclusion (TIDE) score and tumor mutation burden (TMB), and higher likelihood of benefiting from immunotherapy. Furthermore, the genomic changes of six LMRGs (CD79A, HACD1, CYP17A1, SLCO1B3, ANGPTL4, and LDHA) were responsible for the difference in susceptibility to LUAD by greatly influencing B-cell activation. Generally speaking, the LMRG model is a reliable independent biomarker for predicting adverse outcomes in LUAD patients and has the potential to facilitate risk-stratified immunotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Liang Cheng, Harbin Medical University, China
Reviewed by: Magdalena Julita Orzechowska, Medical University of Lodz, Poland
Yi-Qing Qu, Shandong University, China
This article was submitted to Molecular and Cellular Pathology, a section of the journal Frontiers in Cell and Developmental Biology
ISSN:2296-634X
2296-634X
DOI:10.3389/fcell.2022.730132